Bolt Biotherapeutics, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 10.81 million compared to USD 16.98 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.45 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.735 USD | +0.42% | -0.72% | -34.38% |
20/05 | Bolt Biotherapeutics, Inc. Announces Management Changes | CI |
20/05 | Bolt Biotherapeutics, Inc. Announces Chief Executive Officer Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.38% | 27.91M | |
+16.44% | 122B | |
+18.94% | 114B | |
+19.62% | 25.71B | |
-25.37% | 19.02B | |
-20.21% | 15.83B | |
-20.20% | 15.32B | |
-47.37% | 14.88B | |
+59.91% | 14.82B | |
+4.35% | 14.1B |
- Stock Market
- Equities
- BOLT Stock
- News Bolt Biotherapeutics, Inc.
- Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024